Diabetes
🇺🇸 FDA Page 2FDA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Unlock global diabetes market insights. Get critical pharma intelligence on R&D, regulatory approvals, and investment opportunities for diabetes treatments.
Showing 13–24 of 30 articles
Tracking Cellular Disruptions in Type 1 Diabetes: Insights for Pharma
FDA Approves LANGLARA Interchangeable Biosimilar to Lantus Insulin - Lannett Company Enters Diabetes Market
COFEPRIS Drug Approvals 2026: What You Need to Know
Novo Nordisk's Oral Ozempic Becomes First FDA-Approved Pill GLP-1 for Type 2 Diabetes with Cardiovascular Protection
Inflation Reduction Act Drug Pricing: Impact on FDA Negotiations & Innovation 2026
SURPASS-CVOT Trial Results: Implications for Mounjaro's Cardiovascular Safety and FDA Labeling
GLP-1 Eating Disorder Risk: What You Need to Know
Ascletis Completes Enrollment for ASC30 Oral GLP-1 Diabetes Drug Phase II Trial
Ascletis Completes Enrollment in Phase II Trial of ASC30 Oral GLP-1 Diabetes Drug
COFEPRIS Drug Approvals 2026: Key Trends and Healthcare Implications
Novo Nordisk's Oral Semaglutide Shows Promise as First GLP-1 Therapy for Children with Type 2 Diabetes
Lupin Launches Generic Dapagliflozin-Metformin XR Tablets in US as Xigduo XR Alternative